NZ755725A - Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase - Google Patents
Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidaseInfo
- Publication number
- NZ755725A NZ755725A NZ755725A NZ75572518A NZ755725A NZ 755725 A NZ755725 A NZ 755725A NZ 755725 A NZ755725 A NZ 755725A NZ 75572518 A NZ75572518 A NZ 75572518A NZ 755725 A NZ755725 A NZ 755725A
- Authority
- NZ
- New Zealand
- Prior art keywords
- galactosidase
- recombinant human
- protein
- alpha
- fabry
- Prior art date
Links
- 102000005840 alpha-Galactosidase Human genes 0.000 title abstract 5
- 108010030291 alpha-Galactosidase Proteins 0.000 title abstract 5
- 238000011285 therapeutic regimen Methods 0.000 title 1
- 208000024720 Fabry Disease Diseases 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762442537P | 2017-01-05 | 2017-01-05 | |
| PCT/IL2018/050018 WO2018127920A1 (en) | 2017-01-05 | 2018-01-05 | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ755725A true NZ755725A (en) | 2023-06-30 |
Family
ID=62790830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ755725A NZ755725A (en) | 2017-01-05 | 2018-01-05 | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12194079B2 (enExample) |
| EP (1) | EP3565583A4 (enExample) |
| JP (2) | JP2020504131A (enExample) |
| KR (2) | KR20190103320A (enExample) |
| CN (2) | CN110381987A (enExample) |
| AU (1) | AU2018205891B2 (enExample) |
| BR (1) | BR112019013920A2 (enExample) |
| CA (1) | CA3048151A1 (enExample) |
| CL (1) | CL2019001867A1 (enExample) |
| IL (1) | IL267863A (enExample) |
| MX (1) | MX2019008076A (enExample) |
| NZ (1) | NZ755725A (enExample) |
| WO (1) | WO2018127920A1 (enExample) |
| ZA (1) | ZA201904850B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12020820B1 (en) * | 2017-03-03 | 2024-06-25 | Cerner Innovation, Inc. | Predicting sphingolipidoses (fabry's disease) and decision support |
| AR120055A1 (es) * | 2019-06-11 | 2022-02-02 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal |
| CN116419759A (zh) * | 2020-11-13 | 2023-07-11 | 韩美药品株式会社 | 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的神经病中的用途 |
| CN116419760A (zh) * | 2020-11-13 | 2023-07-11 | 韩美药品株式会社 | 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的肾病中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| CA2052728A1 (en) | 1991-10-03 | 1993-04-04 | Guy Ampleman | Glycidyl azide polymer |
| JP5570677B2 (ja) * | 2002-04-25 | 2014-08-13 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | α−ガラクトシダーゼＡ欠損症の治療 |
| JP5137814B2 (ja) | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート |
| US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| US8742079B2 (en) | 2007-08-20 | 2014-06-03 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
| US9194011B2 (en) * | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| US20120230974A1 (en) | 2009-11-17 | 2012-09-13 | Protalix Ltd | Alkaline alpha galactosidase for the treatment of fabry disease |
| HUE030959T2 (en) | 2010-03-02 | 2017-06-28 | Protalix Ltd | Stabilized alpha-galactosidase and its uses |
| AU2011356137A1 (en) * | 2011-01-20 | 2013-08-15 | Protalix Ltd. | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells |
| WO2014120900A1 (en) * | 2013-01-31 | 2014-08-07 | Icahn School Of Medicine At Mount Sinai | Enhanced therapeutic regimens for treating fabry disease |
-
2018
- 2018-01-05 AU AU2018205891A patent/AU2018205891B2/en active Active
- 2018-01-05 MX MX2019008076A patent/MX2019008076A/es unknown
- 2018-01-05 KR KR1020197023039A patent/KR20190103320A/ko not_active Ceased
- 2018-01-05 CN CN201880016068.5A patent/CN110381987A/zh active Pending
- 2018-01-05 NZ NZ755725A patent/NZ755725A/en unknown
- 2018-01-05 CA CA3048151A patent/CA3048151A1/en active Pending
- 2018-01-05 JP JP2019536488A patent/JP2020504131A/ja active Pending
- 2018-01-05 CN CN202410140178.XA patent/CN117959455A/zh active Pending
- 2018-01-05 KR KR1020247008410A patent/KR20240042110A/ko not_active Ceased
- 2018-01-05 WO PCT/IL2018/050018 patent/WO2018127920A1/en not_active Ceased
- 2018-01-05 US US16/476,084 patent/US12194079B2/en active Active
- 2018-01-05 EP EP18736643.0A patent/EP3565583A4/en active Pending
- 2018-01-05 BR BR112019013920A patent/BR112019013920A2/pt unknown
-
2019
- 2019-07-04 CL CL2019001867A patent/CL2019001867A1/es unknown
- 2019-07-04 IL IL267863A patent/IL267863A/en unknown
- 2019-07-24 ZA ZA2019/04850A patent/ZA201904850B/en unknown
-
2022
- 2022-12-01 JP JP2022192939A patent/JP2023022244A/ja active Pending
-
2025
- 2025-01-10 US US19/015,746 patent/US20250134968A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250134968A1 (en) | 2025-05-01 |
| CA3048151A1 (en) | 2018-07-12 |
| US12194079B2 (en) | 2025-01-14 |
| WO2018127920A1 (en) | 2018-07-12 |
| RU2019124280A (ru) | 2021-02-06 |
| CL2019001867A1 (es) | 2019-10-04 |
| KR20190103320A (ko) | 2019-09-04 |
| AU2018205891B2 (en) | 2024-11-07 |
| CN110381987A (zh) | 2019-10-25 |
| CN117959455A (zh) | 2024-05-03 |
| JP2020504131A (ja) | 2020-02-06 |
| JP2023022244A (ja) | 2023-02-14 |
| MX2019008076A (es) | 2019-08-29 |
| EP3565583A1 (en) | 2019-11-13 |
| EP3565583A4 (en) | 2020-12-02 |
| RU2019124280A3 (enExample) | 2021-09-14 |
| KR20240042110A (ko) | 2024-04-01 |
| IL267863A (en) | 2019-09-26 |
| US20200155654A1 (en) | 2020-05-21 |
| BR112019013920A2 (pt) | 2020-02-04 |
| AU2018205891A1 (en) | 2019-08-15 |
| ZA201904850B (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Perez et al. | Update on the use of immunoglobulin in human disease: a review of evidence | |
| NZ755725A (en) | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase | |
| MX2010004508A (es) | Suministro de agentes activos. | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| HK1202776A1 (en) | Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy | |
| MX2023012271A (es) | Medicina terapeutica para enfermedades fibrosas. | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| AU2020231505A8 (en) | Sequential intravitreal administration of AAV gene therapy to contralateral eyes | |
| WO2019157056A8 (en) | Treatment of patients with classic fabry disease | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| HK1255584A1 (zh) | 使用阿坎酸及d-环丝胺酸的联合疗法 | |
| JOP20190019A1 (ar) | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| RU2018132694A (ru) | Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста | |
| PH12021550656A1 (en) | Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses | |
| EP4327869A3 (en) | Methods of treating fabry patients having renal impairment | |
| CN108014336B (zh) | 一种用于治疗眼自身免疫性葡萄膜炎的药物组合物 | |
| KR20190120396A (ko) | 족부의 제1 중족지절 관절의 이상성을 치료하는데 사용하기 위한 신경근육성 독소 | |
| HK1225969A1 (zh) | 利用低剂量的拉喹莫德治疗克隆氏病 | |
| Bondada et al. | Cerulein-treated Ras-activated mice develop painful chronic pancreatitis | |
| Pappy MD et al. | Peripheral Nervous Stimulator Reduces Refractory Pain in Patient with Chronic Lower Extremity Pain | |
| RU2417091C2 (ru) | Способ лечения артрозо-артритов | |
| Willyard | Companies compete over mutation-specific melanoma drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2025 BY MS. PETRA OLK Effective date: 20240103 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JAN 2026 BY DENNEMEYER AND CO. SARL Effective date: 20250103 |